Keyword: EuroBiotech Report
Disley joined Mogrify and participated in its seed round to advance technology for direct reprogramming between mature cell types.
Joe Anderson stepped down as CEO in September to take up the chief investment officer position but now finds himself back in charge of the company.
The actions are part of the biotech’s ongoing efforts to seek a way out of its R&D-triggered troubles.
In this week's EuroBiotech Report, AstraZeneca clears out cancer projects, uniQure's hemophilia B drug clears test and Grey Wolf raises £10 million.
In our EuroBiotech roundup this week, DBV shares resubmission timeline, British Library pens deal to add lab capacity and ADC starts Imfinzi trial.
The PD-L1 combination trials led the clear out, and the immuno-oncology drugs tested in those studies feature heavily in the earlier-phase cull.
The deal sees Sygnature take a stake in Pathios in part payment for its involvement in the Oxford-based biotech’s hit-to-lead program.
The action returns full rights to the candidate to Arcturus Therapeutics, which plans to file an IND by the end of the year.
The series A, which was backed by Andera Partners and Canaan, will fund work to render more tumors vulnerable to checkpoint inhibitors.
The update suggests FIX activity increases seen at six weeks are sustainable, giving uniQure a boost as it races Spark Therapeutics to market.